Phase 2 N=210 Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
Non Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 70.9 % of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=419 AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Anticancer Treatment
Primary: Progression Free Survival (PFS) by Investigator Assessment — 10.1; 4.4 Months — p=<0.001
Phase 2 N=22 Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M
Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 77.3 percentage of patients
Phase 2 N=171 Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific
Non-Small Cell Lung Cancer
Primary: ORR According to RECIST 1.1 by Independent Review — 62.0 % of participants
Phase 3 N=3,014 Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
Lung Cancer
Primary: Overall Survival (OS) — 22.8 Months
Phase 3 N=29 Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours
Locally Advanced or Metastatic EGFR T790M+ NSCLC
Primary: Number of Subjects With Adverse Events (AEs) as a Measure of the Safety and Tolerability of Osimertinib in Combination With Durvalumab — 12; 8; 8; 4 Participants
Phase 3 N=692 AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Primary: Median Progression Free Survival (PFS) (Months) — 18.9; 10.2; 17.8; 9.8 Months — p=<0.0001
N/A N=314 T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
Non-small Cell Lung Cancer Stage III · Non-Small-Cell Lung Cancer Metastatic
Primary: Number of Patients With T790M Mutation Detected by Amplification Refractory Mutation System (ARMS) Assay — 97 participants
Phase 3 N=256 T790M Plasma Testing Methodology Comparison and Clinical Validation
Lung Cancer
Primary: Concordance — 91.3; 66.8; 82.7; 86.1 percentage of aggrement
Phase 4 N=60 Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Objective Tumour Response (Complete Response [CR], Partial Response [PR]) as Assessed by the Investigator According to the RECIST Version 1.1 — 50 Percentage of…
Phase 2 N=154 A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Primary: Proportion of Patients With a Given Tumour Genetic and Proteomic Marker at the Point of Disease Progression — 2.0; 3.9; 2.0; 3.9 Percentage of participants
Phase 2 N=88 Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT) — 0; 0 Participants
Phase 3 N=492 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 5.6; 5.5 Months — p=0.0122
Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Phase 2 N=15 Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
Locally Advanced or Metastatic NSCLC
Primary: Objective Response Rate — 0 Participants
Phase 3 N=168 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: 2-year Overall Survival Rate — 67; 70 percentage of participants — p=0.44
Phase 2 N=41 A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Best Overall Response (BOR) in Participants With T790M Mutation — 0; 1; 7; 6 Participants
Phase 2 N=129 LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response (OR) as Determined by RECIST 1.0 — 62.0 percentage of participants
Phase 2 N=17 A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Non Small Cell Lung Cancer
Primary: Objective Response Rate as Assessed by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST 1.1) — 8 Participants
N/A N=24 Understanding Mechanisms of Acquired Resistance to BIBW2992
Non-small Cell Lung Cancer · EGFR Mutations
Primary: Number of Participants That Have a T790M Mutation on Their Progression Biopsy. — 4 Participants
Phase 2 N=218 BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 13.0 percentage of participants
Phase 2 N=25 Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR)
Non Small Cell Lung Cancer
Primary: Percentage of Participants With Progression Free Survival — 64 percentage of participants
N/A N=4 Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Phase 4 N=24 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Among Erlotinib-Treated Participants With the EGFR Mutation — 13.7 months
Phase 2 N=155 Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M
Non Small Cell Lung Cancer Metastatic
Primary: Progression Free Survival (PFS) — 15.4; 12.3 months — p=0.84
Phase 3 N=375 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v 1.1) — 9.574 months
Phase 2 N=11 Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer · Stage IIIB Non-Small Cell Lung Cancer · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) Determined as the Percentage of Patients Achieving Complete Response or Partial Response as Respectively Defined in RECIST 1.1 — 1 Participants
Phase 3 N=14 Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
Carcinoma, Non-Small-Cell Lung
Primary: Safety Assesment — 92.9; 35.7; 35.7; 21.4 Percentage of participants
Phase 2 N=30 A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)…
Phase 4 N=62 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Non-Squamous Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 12.846 Months